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Available online 2 December 2015Objectives: Enzymatic activity of lipoprotein-associated phospholipase A2 (Lp-PLA2) mediates vascular in-
ﬂammation in coronary heart disease (CHD). Calibration of Lp-PLA2 activity measurements using a recombinant
enzyme was performed to assess intra- and inter-laboratory assay precision and accuracy in routine clinical set-
tings.
Design and methods: Test performance assessment included recovery, analytical sensitivity, linear range,
within-lab and site-to-site precision, interference, and analyte stability. Results using the Beckman-Coulter
AU400 analyzer were compared to other chemistry analyzers.
Results: Lp-PLA2 activity ranged from 84 to 303 nmol/min/mL in 300 subjects, with 82.0% and 18.0% mea-
surements below and at or above a cut-point of 225 nmol/min/mL, respectively. Results of matched K2-EDTA
plasma and serum (n = 131) were similar with a slope of 1.00, y-intercept of 0.05, and R-value of 0.988. Mean
recovery ranged from 90 to 106% of baseline after storage at different temperatures and timeperiods. Limit of de-
tectionwas ≤10 nmol/min/mL, without deviation from linearity between 10 and 382 nmol/min/mL. Endogenous
substances andmedications did not interferewith the activitymeasurements. Overall intra- and inter-laboratory
precision among three sites showed coefﬁcients of variation of ≤3.8% and ≤5% respectively. Limit of quantitation
was 1.3 nmol/min/mL. Method comparison studies for multiple analyzers demonstrated slopes, intercepts or R2
coefﬁcients ranging from 0.96 to 1.06,−5.6 to 2.0, or 0.997 to 0.999, respectively.
Conclusion: Analytical performance of the calibrated PLAC® test for Lp-PLA2 enzyme activity assay in CHD is
resistant to a wide variety of pre-analytical factors, with site-to-site reproducibility on multiple analyzers sufﬁ-
cient to standardize results in diverse laboratory settings.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Standardization1. Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating
enzyme whose activity contributes to atherosclerotic cardiovascular
diseases (CVD) [1,2] and may be assayed by its cleavage of synthetic
substrates containing the sn-2 position of endogenous phospholipid
substrates [3]. Lp-PLA2 contributes to plaque development by cleaving
oxidized LDL to yield lysophatidylcholine and oxidized free fatty acids,
which are pro-inﬂammatory and pro-apoptotic in the atheromatousoronary heart disease; CVD,
enzyme-linked immunosorbent
limit of quantitation; Lp-PLA2,
binant Lp-PLA2.
er Point Boulevard, South San
sky).
ty of Clinical Chemists. Publishedenvironment of the arterialwall [3–5]. Clinical studies have demonstrat-
ed that Lp-PLA2 enzyme activity is useful in patient management since
levels predict CVD events associated with coronary heart disease (CHD)
and ischemic stroke, not only in patients with risk factors alone (primary
prevention), but also in those with established disease (secondary pre-
vention) [6]. The Lp-PLA2 Studies Collaboration analyzed 32 studies and
highlighted differences in Lp-PLA2 enzyme activity levels, which varied
primarily due to the use of different substrates [6]. These data suggest
that clinical use of Lp-PLA2 enzymatic activity measurements for patient
management may be optimized by assay harmonization.
Inter-laboratory agreement of enzyme activity measurements is a
goal in laboratory medicine due to variability in results among different
laboratories [7]. Enzymes are a special class of analyte requiring stan-
dardization of measurements since catalytic activity depends on testing
conditions, and measurements may vary substantially between labora-
tories due to changes in reaction conditions. Such variability mayby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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sults [7], particularly in the context of published assay performance
data. The magnitude of activity measurements depends on the compo-
nents of the reaction system and the analytical conditions, but may be
optimized by use of a reference measurement procedure. Two tests for
Lp-PLA2 measurements include the same recombinant Lp-PLA2 (rLp-
PLA2) protein [8–11] for calibrating measurements of enzyme concen-
tration by ELISA [12] or enzyme activity by colorimetric detection of
cleaved synthetic substrate. An additional requirement for enzyme ac-
tivity standardization is a reference interval based on use of a reference
measurement system and clinical populations with similar characteris-
tics to obviate potential inﬂuences due to ethnicity and/or environment
[7].
The clinical value of Lp-PLA2 activity measurements depends on
broad integration of knowledge of the enzyme's physiology, inﬂamma-
tory role, demographic variation, and clinical practice, together with in-
terpretation of assay results optimized for CVD outcomes. In this work,
we report the use of a recombinant Lp-PLA2 enzyme to calibrate results
of the PLAC® Test for Lp-PLA2 activity, which utilizes an activity cut-
point of 225 nmol/min/mL targeted for use in primary prevention of
CHD. The objective of this study is to demonstrate the analytical perfor-
mance of the activity assay, including assay precision, sensitivity, linear-
ity, specimen stability, and site-to-site variability, thus satisfying
requirements [7] for use as a standardized enzyme activity assay on a
variety of automated chemistry analyzers in diverse clinical laboratory
settings.
2. Materials and methods
2.1. Specimens
Human plasma and serum were obtained as archival or fresh sam-
ples from vendors (Bioreclamation IVT, LAB Express, and ProMedDx)
who collected blood samples from consented donors, or as prospective
samples from human volunteers (Diadexus) who provided informed
consent, under protocols approved by an Institutional Review Board of
participating facilities using standard operating procedures. Demo-
graphic information was obtained for each subject and was limited to
age, gender, and race; no other clinical information was obtained. De-
tails of specimen handling and storage are provided in the Supplemen-
tal information.
2.2. Lp-PLA2 enzyme activity
Measurement of plasma or serum Lp-PLA2 activity was performed
with the PLAC Test for Lp-PLA2 Activity (Diadexus) using recombinant
Lp-PLA2 (rLp-PLA2) enzyme as a standard for calibration as previously
described [9]. rLp-PLA2 was manufactured with proprietary procedures
and used to develop a set of master calibrators to standardize each pro-
duction lot due to the absence of a recognized national reference stan-
dard. Patient samples, calibration standards, or high and low controls
were added to a reaction buffer containing the substrate, 1-myristoyl-
2-(4-nitrophenylsuccinyl) phosphatidylcholine. Substrate hydrolysis
by Lp-PLA2 yielded 4-nitrophenol, which was measured spectrophoto-
metrically using the BeckmanCoulter AU400 clinical chemistry analyzer
with optimized, instrument-speciﬁc settings at 410 nm and an assay
time of 8.5 min. Five rLp-PLA2 calibrators were used to generate a stan-
dard curve ﬁt of change in absorbance versus Lp-PLA2 activity level in
nmol/min/mL. This standard curve was utilized to determine sample
Lp-PLA2 activity.
Calibrated sample results were compared to uncalibrated results
using two different lots of substrate. A slope from a non-enzymatic
curve of absorbances of known solutions of 4-paranitrophenol
(PNP) plotted by nmol was used to convert uncalibrated results to
Activity units. Sample results were calculated by the followingequation: Lp-PLA2 activity nmol/min/mL = sample kinetic slope/
PNP slope/0.025 mL.
2.3. Sensitivity and linearity
The limit of blank (LoB) and limit of detection (LoD) were deter-
mined using calibrators and native K2EDTA plasma, respectively, using
analytical approaches described in CLSI EP17-A2 [13], and limit of quan-
titation (LoQ) was determined using human plasma and non-human
plasma dilutions (see Supplemental information).
To determine assay linearity, Lp-PLA2 activity was measured in tripli-
cate with reagents from three kit lots using a specimen dilution series at
13 different levels for each pair of high and low samples. Three high
(~380nmol/min/mL) and three low (b10nmol/min/mL) Lp-PLA2 activity
specimens were used from individual donors. To generate high activity
specimens for this study, rLp-PLA2 protein was spiked into specimens
with high native Lp-PLA2 activity. To generate specimens with low activ-
ity, patient specimens with low native Lp-PLA2 activity were dilutedwith
chicken plasma (Bioreclamation IVT, P/N CHLPLEDTA2) to yield Lp-PLA2
activity values of b10 nmol/min/mL.
2.4. Sample matrix
Freshly drawn blood samples were collected from 21 donors in ﬁve
different tube typeswith serumand varying anticoagulant (K2, K3 EDTA
and heparin). After collection processing, sample aliquots were stored
at 2–8 °C for one day, and then tested in triplicate. For data analysis,
the three replicates for each tube type were averaged and then com-
pared to K2−EDTA plasma results obtained without a separator using
a calculated percent recovery and Deming regression. The activity
range of the samples, 94 to 323 nmol/min/mL, encompassed 95% of
the observed expected values range.
2.5. Assay robustness
To determine assay robustness, Lp-PLA2 activity measurements
were performed on serum samples from 148 subjects using one reagent
lot in the absence or presence of ﬁve rLP-PLA2 calibrators ranging from0
to 400 ng/mL, using two different lots of the substrate, 1-myristoyl-2-
(4-nitrophenylsuccinyl) phosphatidylcholine.
2.6. Lp-PLA2 enzyme activity cut-point
In order to determine clinical performance for the prognostication of
future CHD events, an Lp-PLA2 activity cut-point of 225 nmol/min/mL
was established to enable assignment of clinically relevant high or low
values. For reference, a value of 225 nmol/min/mL was derived from
the JUPITER Study [14] based on determinations of Lp-PLA2 activity
using archival plasma samples previously stored at ≤−70 °C for this
study.
2.7. Specimen stability
To determine the effects of temperature and time on the stability of
the Lp-PLA2 activity result, prospectively-collected specimens from 26
subjects were assayed on the day of collection with results used as the
“baseline”; then these same samples were analyzed after they were
stored at different temperatures for varying time periods. To assess
the stability of Lp-PLA2 activity in unfrozen or frozen specimens, Lp-
PLA2 activity was measured after specimen storage at 4 °C or 26 °C for
up to threemonths or at−20 °C or−70 °C for up to 26months, respec-
tively. For freeze/thaw study samples, the measured activity value after
each freeze thaw cycle was compared to the fresh unfrozen sample
value. Measurements of Lp-PLA2 activity for all temperatures and time
intervals were compared to baseline results to determine average re-
covery values.
Table 1
Expected Lp-PLA2 activity values.
Percentile Lp-PLA2 activity (nmol/min/mL)
All Male Female
(n = 300) (n = 154) (n = 146)
Minimum 50 70 50
2.5 84 92 74
5 94 102 86
20 129 144 123
25 137 149 130
33 148 155 139
50 167 176 154
67 196 204 179
75 211 219 200
80 221 232 215
95 276 295 264
97.5 303 329 300
99 369 397 339
Maximum N400 N400 370
Mean 176 186 166
S.D. 58 59 55
Shown are the expectedminimum, maximum andmean values and also the values at the
indicated percentiles for Lp-PLA2 enzyme activity (nmol/min/mL) for the entire subject
cohort and by gender. (S.D., standard deviation).
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To determine whether substances may alter the Lp-PLA2 activity
result, measurements were performed to assess both endogenous
(albumin, bilirubin (conjugated and unconjugated), cholesterol,
hemoglobin, and triglycerides) and exogenous (acetaminophen,
acetylsalicylic acid, atorvastatin, clopidogrel bisulfate, diphenhydra-
mine, fenoﬁbrate, lisinopril, metformin, niacin, tolbutamide, warfa-
rin, and vitamin C) substances by spiking each substance into four
K2-EDTA plasma and four serum specimens (see Supplemental
Information).
2.9. Reagent stability
Assessments of reagent stability, open bottle stability, and on board
analyzer stability were performed to determine their effects on Lp-PLA2
activity measurements (see Supplemental Information).
2.10. Assay precision
To determine intra-laboratory precision, Lp-PLA2 activity was mea-
sured using four plasma specimens and two kit control samples
containing buffer and rLp-PLA2 activity ranging from 113 to 315
nmol/min/mL. Each run of measurements was performed in duplicate
using reagents from three kit lots, with the performance of two runs
per day for a 20 day period, yielding 80 results for each kit lot. To deter-
mine inter-laboratory (site-to-site) reproducibility, different operators
at three independent laboratories assayed Lp-PLA2 activity in the same
set of four K2EDTA and four serum specimens with Lp-PLA2 activity
ranging from 22 to 380 nmol/min/mL. Assays were performed at each
laboratory daily for ﬁve days over a two week period using the same
kit lot.
2.11. Method comparisons
To assess the performance of the Lp-PLA2 activity assay on different
chemistry analyzers, 40 specimenswith Lp-PLA2 activity values ranging
from5 to 365nmol/min/mLwere tested on various analyzers optimized
with instrument speciﬁc settings. Data for each analyzer were com-
pared to those yielded by the Beckman Coulter AU400 analyzer by
Deming regression analysis [16].
2.12. Statistical analysis
To determine the limit of quantitation (LOQ), precision proﬁles
using CLSI EP17-A2 guidelines [13] and a target coefﬁcient of variation
(CV) of 20%were used. To determine assay linearity, Lp-PLA2 activity re-
sultswere compared to expected values using linear regression, and the
degree of non-linearity was determined for each data set by second and
third order polynomial regression plots using CLSI EP06-A guidelines
[15]. A t-test was performed to determine the statistical signiﬁcance of
the non-linear coefﬁcients for selection of best polynomial ﬁt based on
the lowest standard error of regression. To calculate deviation from lin-
earity for each concentration, the best ﬁt linear y-value was subtracted
from the best ﬁt polynomial y-value at that level with conversion of a
difference to a percent value. Matrix and method comparison studies
were analyzed by Deming regression [16].
To estimate the variance components for each parameter in the pre-
cision analyses, the restrictedmaximum likelihood (REML)method and
a random effects ANOVA model were used, with the latter performed
separately for each kit lot. To evaluate site-to-site precision, analyses
were performed using JMP software (version 9.0.2) and nested linear
components of variance model including two factors, “site” and “day,”
with “day” nested within “site” following CLSI EP05-A3 guidelines [17].
For the cut-point determination, the JUPITER investigators assessed
the cardiovascular risk by Cox proportional hazard regression tocalculate hazard ratios across quartiles for Lp-PLA2 Activity by a model
minimally adjusted for LDL-cholesterol and a multivariate model ad-
justed for age, sex, smoking status, family history of premature athero-
sclerosis, bodymass index, systolic blood pressure, HDL-cholesterol and
hsCRP.
3. Results
3.1. Analytical performance
Determination of the expected value ranges for Lp-PLA2 activity for
the general population was performed using archival K2EDTA plasma
specimens obtained from 300 random subjects with age ranging from
35 to 75 years (median= 55.7 years). The population evaluated includ-
ed a gender distribution of 51%men and 49% women and a racial distri-
bution of 38% Caucasian, 32% African-American, 21% Hispanic and 9%
Asian subjects. The central 95th percentile distribution of Lp-PLA2
activity was 84 to 303 nmol/min/mL for all subjects, and 92 to 329
nmol/min/mL or 74 to 300 nmol/min/mL for men or women, respec-
tively, as shown in Table 1.
Analysis of plasma specimens from 5446 subjects associated with
primary prevention of CHD in the placebo arm of the JUPITER Study
[14] demonstrated that Lp-PLA2 activity in the highest quartile was as-
sociated with a hazard ratio (HR) for CHD events of 2.83 (C.I. = 1.63–
4.94) or 2.15 (C.I. 1.13–4.08) in minimally-adjusted or fully-adjusted
models, respectively. These data enabled the derivation of a cut-point
of 225 nmol/min/mL to differentiate those at either increased,
i.e., high Lp-PLA2 (≥225 nmol/min/mL), or decreased CHD event risk,
i.e., low Lp-PLA2 (b225 nmol/min/mL) risk for CHD events. Use of the
cut-point identiﬁed 82.0% or 18.0% of the 300 subjects with low or
high activity, respectively; similarly, the cut-point identiﬁed 79% and
85% of men and women, respectively, with low activity, and 21% and
15% of men and women, respectively, with high activity. No clinical in-
formation, i.e., health or disease status, was available for the analysis.
Further analyses yielded an LOB of 0.4 nmol/min/mL, an LOD of 0.74
nmol/min/mL, and an LOQ of 1.3 nmol/min/mL. Use of weighted linear
regression to analyze assay linearity yielded a range of 6 to 382
nmol/min/mL, as shown in Table S1, with deviation from linearity less
than or equal to 10%. Assessment of intra-laboratory variability using
three kit lots during a 20 day period in the Lp-PLA2 activity range of
113 to 315 nmol/min/mL yielded the following within-laboratory com-
posite CVs: within-run, ≤1.5%; between-run, ≤1.8%; day-to-day, ≤1.5%;
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activity was measured using two different substrate lots in the ab-
sence of rLp-PLA2 calibration. Results were converted to activity
units with a factor derived from a non-enzymatic measurement
using 4-nitrophenol, as previously described [6,20,21]. Results
showed an 18% difference in measurements; no statistically signiﬁ-
cant difference was observed between the lots using rLp-PLA2 cali-
bration, as shown in Fig. 1.Fig. 2. Comparison of K2EDTA and serum Lp-PLA2 activity measurements. Lp-PLA2 activity
measurements (nmol/min/mL) were determined for 131 matched K2EDTA plasma and
serum samples from individual donors and plotted as shown. The data demonstrated a
slope of 1.00, an intercept of 0.05 nmol/min/mL, and anR value of 0.988 byDeming regres-
sion [16].3.2. Sample matrix
To assess potential variability associated with blood specimen types
or plasma collection protocols, Lp-PLA2 activity was measured using
matched serumand plasma specimens, aswell asmatched plasma spec-
imens in different blood collection tubes. As shown in Fig. 2, matched
serum and K2EDTA plasma data from 131 subjects demonstrated a
slope of 1.00 (95% C.I.: 0.974 to −1.029) in the range of 56 to 357
nmol/min/mL, with an intercept of 0.05 (95% C.I.: -1.28 to 1.39) and
an R coefﬁcient of 0.988 by Deming regression analysis [16]. These
data demonstrated comparable Lp-PLA2 activity results for matched
serum or plasma specimens.
To assess the effect of using different blood collection tubes, Lp-PLA2
activity was measured in specimens obtained from 21 subjects distrib-
uted among tubes containing K2EDTA, K2EDTA gel, K3EDTA, and lithium
heparin for plasma, and also serum tubes with and without separator
gel. Comparison of thematched K2EDTA gel, K3EDTA, and lithium hepa-
rin results with those for K2EDTA or serum showed slopes ranging from
1.00 to 1.03 with intercepts ranging from−1.03 to 0.93 and R coefﬁ-
cients ranging from 0.997 to 0.999, thus demonstrating the indepen-
dence of the Lp-PLA2 activity result from blood collection tube type, as
shown in Table S2.Fig. 1. Comparison of Lp-PLA2 activity measurements without and with rLp-PLA2 calibra-
tion. Lp-PLA2 activity was determined for 139 serum specimens using two different sub-
strate lots, A and B, without (uncalibrated, open circles) or with (calibrated, ﬁlled
circles) use of rLp-PLA2 calibrators. Activity units for both data sets are expressed in
units of nmol/min/mL. The calibrated results were based on quantitation from a standard
curve using Lp-PLA2 enzyme calibrators and the uncalibrated results were calculated uti-
lizing a factor based on the slope of 4-nitrophenol absorbance at various concentrations.
Regression parameters from the results using lots A and B for either uncalibrated or cali-
brated data, and the relative recovery rate (%) between the two lots are shown.3.3. Sample storage
Since some enzymatic proteins demonstrate lability during storage,
the potential variability in Lp-PLA2 activity results due to specimen stor-
age conditions over time was evaluated. Assessment of K2EDTA plasma
specimens at 4 °C for up to three months and at 26 °C for up to one
month demonstrated average recovery values of greater than or equal
to 95% for Lp-PLA2 activity compared to those at baseline, as seen in
Table 2. Lp-PLA2 activity ranged from 62 to 239 nmol/min/mL. Evalua-
tion of frozen storage conditions for K2EDTA plasma obtained from 10
subjects and stored at −20 °C or −70 °C for durations of up to 26
months showed differences of less than 10% upon comparison of the av-
erage recovery at each time point compared to the baseline value, as
shown in Table 2. No statistically signiﬁcant differences were observed
for values between serum and K2EDTA plasma after frozen storage
(data not shown). Similarly, serum and K2EDTA plasma specimens
(n = 20) subjected to seven freeze–thaw cycles demonstrated average
recovery of 95 to 100% at−20 °C and 96 to 97% at ≤−70 °C compared to
baseline Lp-PLA2 activity values.3.4. Substance interference
Since patients with CHD commonly have associated conditions and
usemedications as part of routinemanagement, the potential variabilityTable 2
Lp-PLA2 activity stability by storage conditions.
Time 2–8 °C 26 °C −20 °C −70 °C
(n = 26) (n = 26) (n = 10) (n = 10)
Day 1 100% 103% 102% 100%
Day 7 95% 102% 97% 98%
Month 1 95% 102% 106% 106%
Month 2 96% 78% 91% 90%
Month 3 97% 70% 101% 102%
Month 13 NA NA 98% 94%
Month 26 NA NA 95% 100%
Average recovery values are shown for Lp-PLA2 activity measurements for the indicated
temperatures and time intervals expressed as a percentage of baseline values. (NA, not
applicable).
Table 4
Method comparison of automated clinical chemistry analyzers.
Clinical chemistry analyzer Intercept
Slope (nmol/min/mL) R2 value
Abbott ARCHITECT c8000/ci8200 1.06 −3.47 0.999
Beckman Coulter AU480 1.00 −3.35 0.999
Beckman Coulter AU640 0.96 2.03 0.999
Beckman Coulter AU5800 0.99 −0.90 0.999
Beckman Coulter DxC600 1.01 −2.38 0.999
Beckman Coulter DxC800 1.03 −4.73 0.999
Roche cobas 6000 (c501) 1.03 −4.48 0.999
Roche cobas 8000 (c502) 1.05 −3.31 0.997
Roche Modular-P 1.05 −5.62 0.999
Siemens Advia 1800 0.99 1.74 0.998
Siemens Advia 2400 0.96 0.58 0.999
Shown are the slopes, intercepts (nmol/min/mL), and R2 coefﬁcient values for Lp-PLA2 ac-
tivity results obtained using the eleven indicated clinical chemistry analyzerswith data for
each compared to those obtained using the Beckman Coulter AU400 analyzer.
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was evaluated. As shown in Table S3, none of the blood components
or medications assessed, including those related to CHD, demonstrated
interference as shown by analyses of average recovery for spiked and
corresponding control samples.
3.5. Inter-laboratory performance
To assess the inter-laboratory variability associatedwith the Lp-PLA2
activity assay, site-to-site reproducibility for three different laboratories
was evaluated. Site-to-site reproducibility in the Lp-PLA2 activity range
of 22 to 380 nmol/min/mL during a 5 day period yielded individual
within-lab precision CVs of 1.4 to 4.2%, as shown in Table 3. Analysis
of site-to-site precision demonstrated CVs ≤ 3.4% for all samples and
total precision CVs ranging from 2.7 to 4.6%.
Since the Lp-PLA2 activity assay kit may be used in a variety of labo-
ratory settings, its reproducibilitywas assessed by testing 40 samples on
different automated chemistry analyzers and comparing the results to
those observed for the Beckman Coulter AU400 analyzer. As seen in
Table 4, method comparison analyses of the analytical performance of
the Lp-PLA2 activity assay using 11 additional chemistry analyzers dem-
onstrated slopes between 0.96 and 1.06 with correlation coefﬁcients
(R2) greater than or equal to 0.997. Analysis of once opened and stored,
capped reagents at 4 °C from three kit lots at 16 weeks demonstrated
average percent recovery ranging from90 to 110% compared to baseline
values. Similarly, use of reagents that were stored uncapped on-board
automated clinical chemistry analyzers for 6 weeks demonstrated aver-
age recovery ranging from 90 to 110% compared to baseline values.
4. Discussion
Clinical interpretation of Lp-PLA2 enzyme activity measurements in
the management of patients at risk for CHD may be optimized by
assay standardization to enhance inter-laboratory agreement and corre-
lation of individual patient results to those observed in published clini-
cal performance data. The clinical use of enzyme activity measurements
requires optimization by assay standardization due tomyriad contribu-
tors to results variability [7], including the following: individual or pop-
ulation heterogeneity phenotypes; specimen collection, handling and
storage protocols; assay interference by endogenous or exogenous
substances; use of different analytical platforms; differences in raw
materials; and differences in laboratory protocols. To enable standardi-
zation ofmeasurements of Lp-PLA2 enzyme activity for patientmanage-
ment, the PLAC Test for Lp-PLA2 Activity kit includes ready-to-use
reagents and a recombinant Lp-PLA2 (rLp-PLA2) enzyme for use as cali-
brators and controls. In the present study, we demonstrate that using
rLp-PLA2 calibrators traceable and consistent to reference material
quantitate reproducible Lp-PLA2 activity assay results, enabling use of
patient specimens from different medical practice environments andTable 3
Analysis of intra-and inter-laboratory precision for K2EDTA plasma and serum specimens.
Sample Mean Within-lab Site-to-site Total
(nmol/min/mL) CV CV CV
Plasma 1 21.9 2.6% 2.7% 3.8%
Plasma 2 108.3 2.1% 2.8% 3.5%
Plasma 3 233.6 1.8% 1.9% 2.7%
Plasma 4 379.5 1.4% 2.3% 2.7%
Serum 1 23.6 4.2% 1.9% 4.6%
Serum 2 102.3 1.7% 3.4% 3.8%
Serum 3 232.3 2.1% 3.1% 3.7%
Serum 4 355.9 2.3% 2.2% 3.2%
Shown are the mean Lp-PLA2 activity results, the within-lab coefﬁcient of variation (CV),
the site-to-site CVs using the Beckman Coulter AU400 analyzer at three independent
sites, and the total CV for each of four K2EDTA plasma and four serum specimens.performance on different automated chemistry analyzers in diverse
clinical laboratory settings.
The Lp-PLA2 enzyme activity assay demonstrated analytical perfor-
mance sufﬁcient for correlating patient results to data in published clin-
ical studies of Lp-PLA2 activity in CVD [14]. The analyses yielded an LOQ
of ≤10 nmol/min/mL for analytical sensitivity, which is sufﬁcient to sup-
port clinical measurements observed for the CHD population, and an
assay linearity range of 6 to 382 nmol/min/mL, which is similar to that re-
ported in an independent analysis [18]. The central 95th percentile of ex-
pected Lp-PLA2 activity values ranged from 84 to 303 nmol/min/mL, with
a higher median value of 176 nmol/min/mL observed for men com-
pared to the 154 nmol/min/mL observed for women. Use of an enzyme
activity cut-point of 225 nmol/min/mL to determine low (below cut-
point) or high (at or above cut-point) activity levels yielded a distribu-
tion of 82% and 18%, respectively, for the population studied, while dis-
tributions of low and high levels for men or women were 79% or 85%
and 21% or 15%, respectively. Comparisons of Lp-PLA2 activity measure-
ments using two substrate lots, without or with rLp-PLA2 calibrators,
demonstrated that rLp-PLA2 calibration increased assay reproducibility
(Fig. 1). Interference testing demonstrated that neither endogenous cir-
culating substances nor medications typically used by patients at risk
for CHD altered Lp-PLA2 activity results, as shown in Table S3.While dif-
ferences in blood matrices may inﬂuence activity results of enzymes,
neither use of serum or plasma, nor blood collection in different tube
types yielded statistically signiﬁcant differences in Lp-PLA2 activity re-
sults. Variations in sample handling with respect to storage in unfrozen
or frozen conditions for clinically relevant time periods did not yield
statistically signiﬁcant differences in Lp-PLA2 activity measurements.
Moreover, Lp-PLA2 enzyme activity measurements remained stable
after multiple freeze–thaw cycles. Therefore, potential variations due
to pre-analytical specimen handling donot affect calibrated Lp-PLA2 en-
zyme activity measurements, in contrast to a prior report for determi-
nations of Lp-PLA2 concentration by ELISA [19].
Analyses of assay performance ondifferent automated chemistry an-
alyzerswith ready-to-use reagents in different laboratories also demon-
strated that calibrated Lp-PLA2 enzyme activitymeasurements achieved
requirements necessary for inter-laboratory agreement and standard-
ized interpretation of activity results stipulated by the International
Federation of Clinical Chemistry and Laboratory Medicine [7]. Compari-
son studies of Lp-PLA2 activity results performed onmultiple automated
chemistry analyzers demonstrated Deming regression line slopes of
0.96–1.06 and correlation coefﬁcients greater than or equal to 0.997,
thus supporting the independence of the measurements from variation
in accuracy due to analysis on various analyzers commonly used in dif-
ferent laboratories. The demonstration of CVs less than or equal to 3.4%
for all samples tested on the same analyzer in three different laborato-
ries by different operators also showed the site-to-site reproducibility
of calibrated Lp-PLA2 activity results. The contribution of ready-to-use
485M.J. Cerelli et al. / Clinical Biochemistry 49 (2016) 480–485kit reagents to site-to-site precision was also shown by the average re-
covery ranging from 90 to 110% of established values, demonstrating
the open bottle stability of the reagents for up to 6 weeks for use in dif-
ferent laboratory operating protocols. The open bottle study demon-
strated stability of uncapped on board buffers and substrate reagents
for up to 6 weeks.
In summary, the PLAC Test for Lp-PLA2 Activity kit utilizes calibration
by a recombinant Lp-PLA2 protein with ready-to-use reagents to
achieve high intra-laboratory and inter-laboratory precision, and also
the requirements stipulated for enzyme activity assay standardization
[7]. The data also demonstrate that a calibrated Lp-PLA2 activity mea-
surement is independent of heterogeneity in the therapeutic manage-
ment of patients at risk for CVD and in pre-analytical processes such
as blood collection and handling common to diverse practice settings.
The clinical value of a standardized Lp-PLA2 enzyme activity assay is
that it may 1) enhance physician interpretation of activity measure-
ments by enabling correlation of an individual patient's result to exten-
sive, published clinical validation data for CVD population outcomes,
and 2) enables harmonization of results obtained on patients from dif-
ferent laboratories with varying operating protocols.
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